In 2004, the therapeutic potential of stem cells persuaded more than 7 million Californians to approve Proposition 71, which allocated a whopping $3 billion for research and development of stem cell-based drugs and therapies that might someday address a medical dictionary’s worth of diseases and conditions.
Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.
Glaucoma is the leading cause of irreversible blindness in the world, affecting more than 80 million people. However, because the disease remains largely asymptomatic as it progresses, researchers estimate that more than 50 percent of individuals are unaware that they’re afflicted until it’s too late.
In a push to further speed clinical development of emerging stem cell therapies, Sanford Stem Cell Clinical Center at UC San Diego Health System was named today one of three new “alpha clinics” by the California Institute for Regenerative Medicine, the state’s stem cell agency.
Richard Kronick, PhD, a health policy expert and faculty member at University of California, San Diego School of Medicine, has been elected to the prestigious Institute of Medicine, the health arm of the National Academy of Sciences and widely regarded as one of the nation’s most respected scientific society.
UC San Diego Sanford Stem Cell Clinical Center is pushing therapeutic stem cell-based science out of the laboratory and closer to real-world medical applications. The unprecedented trials involve potential therapies for spinal cord injuries, Type 1 diabetes and chronic lymphocytic leukemia.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
